Amgen and AstraZeneca report Phase III Tezspire data for EoE

Amgen and AstraZeneca have reported complete results from the Phase III CROSSING trial of Tezspire for adolescent and adult patients with uncontrolled, symptomatic EoE. The trial evaluated 368 participants aged 12 to 80 years who were permitted to continue stable background therapies. The companies will split costs and profits equally following a mid-single-digit royalty to Amgen. Credit: Melnikov Dmitriy / Shutterstock.com. Amgen and AstraZeneca have reported complete results from the Phase III CROSSING clinical trial of Tezspire (tezepelumab-ekko) for adolescent and adult patients with uncontrolled, symptomatic eosinophilic oesophagitis (EoE). Subcutaneous administration of the treatment every four weeks met co-primary endpoints…

Source: Clinical Trials Arena